Alteration of hepatic but not renal transporter expression in diet-induced obese mice

Drug Metabolism and Disposition

Volumn 39, Issue 6, 2011, Pages 992-999

  More, Vijay R ^a   Slitt, Angela L ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1A1; ORGANIC ANION TRANSPORTER 1A4; ORGANIC ANION TRANSPORTER 1B2; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; LIPID DIET; MALE; MOUSE; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE DISTRIBUTION; UPREGULATION;

ANIMALS; BLOTTING, WESTERN; BODY WEIGHT; CYTOKINES; DIETARY FATS; DISEASE MODELS, ANIMAL; FATTY LIVER; HUMANS; KIDNEY; LIVER; MALE; MICE; MICE, INBRED C57BL; OBESITY; ORGAN SIZE; ORGANIC ANION TRANSPORTERS; UP-REGULATION;

MUS;

EID: 79956079563     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.037507     Document Type: Article

References (45)

1. Abernethy DR, Greenblatt DJ, Locniskar A, Ochs HR, Harmatz JS, and Shader RI (1986) Obesity effects on nitrazepam disposition. Br J Clin Pharmacol 22:551-557. (Pubitemid 17177032)
2. Aleksunes LM, Slitt AM, Cherrington NJ, Thibodeau MS, Klaassen CD, and Manautou JE (2005) Differential expression of mouse hepatic transporter genes in response to acetaminophen and carbon tetrachloride. Toxicol Sci 83:44-52. (Pubitemid 40123329)
3. Bergman SJ, Speil C, Short M, and Koirala J (2007) Pharmacokinetic and pharmacodynamic aspects of antibiotic use in high-risk populations. Infect Dis Clin North Am 21:821-846, x.
4. Buist SC and Klaassen CD (2004) Rat and mouse differences in gender-predominant expression of organic anion transporter (Oat1-3; Slc22a6-8) mRNA levels. Drug Metab Dispos 32:620-625. (Pubitemid 38668154)
5. Bush EN, Shapiro R, Nuss M, Kaszubska W, Trevillyan J, Knourek-Segel V, Kennedy M, Adler A, Jirousek M, and Jacobson P (2001) Adiposity, leptin resistance, hyperrphagia, hyperglycemia, glucose intolerance and insulin resistance in C57BL/6J mice fed high fat diets, in Proceedings of the 83rd Annual Meeting and Expo of the Endocrine Society; 2001 Jun 20-23; Denver, CO. The Endocrine Society, Chevy Chase, MD.
6. Cheng Q, Aleksunes LM, Manautou JE, Cherrington NJ, Scheffer GL, Yamasaki H, and Slitt AL (2008) Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity. Mol Pharm 5:77-91. (Pubitemid 351300037)
7. Cheng X, Maher J, Chen C, and Klaassen CD (2005a) Tissue distribution and ontogeny of mouse organic anion transporting polypeptides (Oatps). Drug Metab Dispos 33:1062-1073. (Pubitemid 41002790)
8. Cheng X, Maher J, Dieter MZ, and Klaassen CD (2005b) Regulation of mouse organic anion-transporting polypeptides (Oatps) in liver by prototypical microsomal enzyme inducers that activate distinct transcription factor pathways. Drug Metab Dispos 33:1276-1282. (Pubitemid 41196968)
9. Cherrington NJ, Slitt AL, Maher JM, Zhang XX, Zhang J, Huang W, Wan YJ, Moore DD, and Klaassen CD (2003) Induction of multidrug resistance protein 3 (mrp3) in vivo is independent of constitutive androstane receptor. Drug Metab Dispos 31:1315-1319. (Pubitemid 37310319)
10. Colditz GA, Willett WC, Rotnitzky A, and Manson JE (1995) Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 122:481-486.
11. Davis RC, Castellani LW, Hosseini M, Ben-Zeev O, Mao HZ, Weinstein MM, Jung DY, Jun JY, Kim JK, Lusis AJ, et al. (2010) Early hepatic insulin resistance precedes the onset of diabetes in obese C57BLKS-db/db mice. Diabetes 59:1616-1625.
12. Dawson PA, Lan T, and Rao A (2009) Bile acid transporters. J Lipid Res 50:2340-2357.
13. Day CP and James OF (1998) Steatohepatitis: a tale of two "hits"? Gastroenterology 114:842-845.
14. Edelman AB, Carlson NE, Cherala G, Munar MY, Stouffer RL, Cameron JL, Stanczyk FZ, and Jensen JT (2009) Impact of obesity on oral contraceptive pharmacokinetics and hypothalamicpituitary- ovarian activity. Contraception 80:119-127.
15. Flegal KM, Carroll MD, Ogden CL, and Johnson CL (2002) Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288:1723-1727.
16. Gao J and Xie W (2010) Pregnane X receptor and constitutive androstane receptor at the crossroads of drug metabolism and energy metabolism. Drug Metab Dispos 38:2091-2095.
17. Gentile CL and Pagliassotti MJ (2008) The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. J Nutr Biochem 19:567-576.
18. Ho RH and Kim RB (2005) Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78:260-277. (Pubitemid 41254111)
19. Hummel KP, Dickie MM, and Coleman DL (1966) Diabetes, a new mutation in the mouse. Science 153:1127-1128.
20. Ingalls AM, Dickie MM, and Snell GD (1950) Obese, a new mutation in the house mouse. J Hered 41:317-318.
21. Janvilisri T, Venter H, Shahi S, Reuter G, Balakrishnan L, and van Veen HW (2003) Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem 278:20645-20651. (Pubitemid 36806364)
22. Kiortsis DN, Nikas S, Hatzidimou K, Tsianos E, and Elisaf MS (2003) Lipid-lowering drugs and serum liver enzymes: the effects of body weight and baseline enzyme levels. Fundam Clin Pharmacol 17:491-494. (Pubitemid 36920652)
23. Kruh GD and Belinsky MG (2003) The MRP family of drug efflux pumps. Oncogene 22:7537-7552. (Pubitemid 37487175)
24. Lam JL, Jiang Y, Zhang T, Zhang Y, and Smith BJ (2010) Expression and functional analysis of hepatic cytochrome P450s, nuclear receptors, and membrane transporters in 10-week and 25-week old db/db mice. Drug Metab Dispos 38:2252-2258.
25. Lau YY, Okochi H, Huang Y, and Benet LZ (2006) Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Ther 316:762-771. (Pubitemid 43131004)
26. Lee SA, Wen W, Xu WH, Zheng W, Li H, Yang G, Xiang YB, and Shu XO (2008) Prevalence of obesity and correlations with lifestyle and dietary factors in Chinese men. Obesity (Silver Spring) 16:1440-1447. (Pubitemid 351770534)
27. Lickteig AJ, Fisher CD, Augustine LM, Aleksunes LM, Besselsen DG, Slitt AL, Manautou JE, and Cherrington NJ (2007a) Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease. Drug Metab Dispos 35:1970-1978. (Pubitemid 47481594)
28. Lickteig AJ, Slitt AL, Arkan MC, Karin M, and Cherrington NJ (2007b) Differential regulation of hepatic transporters in the absence of tumor necrosis factor-α, interleukin-1β, interleukin-6, and nuclear factor-κB in two models of cholestasis. Drug Metab Dispos 35:402-409. (Pubitemid 46333903)
29. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with Folin phenol reagent. J Biol Chem 193:265-275.
30. Maher JM, Aleksunes LM, Dieter MZ, Tanaka Y, Peters JM, Manautou JE, and Klaassen CD (2008) Nrf2- and PPARα-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid. Toxicol Sci 106:319-328.
31. Masaki T, Yoshimatsu H, Chiba S, Watanabe T, and Sakata T (2001) Central infusion of histamine reduces fat accumulation and upregulates UCP family in leptin-resistant obese mice. Diabetes 50:376-384. (Pubitemid 32127295)
32. 3-1α-hydroxylase in mice via the long form of the leptin receptor. Arch Biochem Biophys 463:118-127.
33. Okada K, Shoda J, Taguchi K, Maher JM, Ishizaki K, Inoue Y, Ohtsuki M, Goto N, Takeda K, Utsunomiya H, et al. (2008) Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice. Am J Physiol Gastrointest Liver Physiol 295:G735-G747.
34. Pandey SK, Yu XX, Watts LM, Michael MD, Sloop KW, Rivard AR, Leedom TA, Manchem VP, Samadzadeh L, McKay RA, et al. (2007) Reduction of low molecular weight proteintyrosine phosphatase expression improves hyperglycemia and insulin sensitivity in obese mice. J Biol Chem 282:14291-14299.
35. Rabe K, Lehrke M, Parhofer KG, and Broedl UC (2008) Adipokines and insulin resistance. Mol Med 14:741-751.
36. Redinger RN (2009) Fat storage and the biology of energy expenditure. Transl Res 154:52-60.
37. Rodríguez-Martín A, Novalbos Ruiz JP, Martínez Nieto JM, and Escobar Jiménez L (2009) Life-style factors associated with overweight and obesity among Spanish adults. Nutr Hosp 24:144-151.
38. Schuster DP (2009) Changes in physiology with increasing fat mass. Semin Pediatr Surg 18:126-135.
39. Sketris I, Lesar T, Zaske DE, and Cipolle RJ (1981) Effect of obesity on gentamicin pharmacokinetics. J Clin Pharmacol 21:288-293. (Pubitemid 11013037)
40. 3 synthesis in leptin-deficient mice. J Bone Miner Res 25:1711-1723.
41. Uauy R, Albala C, and Kain J (2001) Obesity trends in Latin America: transiting from under- to overweight. J Nutr 131:893S-899S.
42. Vance-Bryan K, Guay DR, Gilliland SS, Rodvold KA, and Rotschafer JC (1993) Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother 37:436-440. (Pubitemid 23072585)
43. Vee ML, Lecureur V, Stieger B, and Fardel O (2009) Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-α or interleukin-6. Drug Metab Dispos 37:685-693.
44. Yamazaki Y, Kakizaki S, Horiguchi N, Sohara N, Sato K, Takagi H, Mori M, and Negishi M (2007) The role of the nuclear receptor constitutive androstane receptor in the pathogenesis of non-alcoholic steatohepatitis. Gut 56:565-574. (Pubitemid 46580514)
45. Zhou SF, Wang LL, Di YM, Xue CC, Duan W, Li CG, and Li Y (2008) Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem 15:1981-2039.